Bryan Johnson: I Just Took the Most Powerful Dose of DMT in the World... Here's What It Was Like
TL;DR
Longevity pioneer Bryan Johnson details taking a record-breaking dose of 5-MeO-DMT as part of his anti-aging protocol. He describes the experience as the most powerful neurological reset achievable, arguing that psychedelics may outperform traditional longevity interventions when used with medical supervision.
🧬 The Longevity Protocol 2 insights
Investigating psychedelics as anti-aging therapy
Johnson approached 5-MeO-DMT as a longevity experiment after psilocybin studies showed reduced inflammation and metabolic resets, adding psychedelics to his rigorous protocol alongside rapamycin and hyperbaric oxygen.
World's most quantified psychedelic session
He administered 9mg intramuscular plus 18mg vaporized 5-MeO-DMT while undergoing comprehensive brain mapping via structural MRI, functional MRI, Kernel optical interface, and real-time EEG.
🚀 The Experience 2 insights
Experiencing raw consciousness without visual hallucinations
Unlike DMT's visual "elves," 5-MeO-DMT induces a non-visual state of infinite depth and "raw intelligence" where the ego completely dissolves within 10 seconds of inhalation.
Total surrender required to avoid existential terror
Users face a choice between panic (feeling existence will "shard" them) or total surrender by releasing all attachment and ego to unlock "unimaginable bliss" and prevent psychological harm.
🧠 Neurological Impact 2 insights
Complete dissolution of the brain's default mode network
While psilocybin dampens the self-rumination engine, 5-MeO-DMT "blasted clean" the default mode network entirely, restoring childlike neural patterns and eliminating rigid "barnacles" of accumulated aging.
Measurable neuroplasticity and metabolic reset effects
Previous psilocybin experiments showed dramatic restoration of youthful brain connectivity and improved blood glucose control from the 99.5th to 99.9th percentile, suggesting whole-body rejuvenation.
⚖️ Lasting Changes & Risks 2 insights
Lasting childlike mental state and improved relationships
Forty-eight hours post-dose, Johnson reported laughing in dreams for the first time since childhood, effortless conflict resolution without ego-defensiveness, and renewed spontaneous excitement about life.
Significant risks of psychosis require medical supervision
Johnson emphasized that psychedelics carry real dangers including permanent psychosis and schizophrenia triggers for predisposed individuals, necessitating precise dosing, proper setting, and licensed professionals.
Bottom Line
When conducted with rigorous medical supervision and quantification, high-dose 5-MeO-DMT may represent the most efficacious single intervention for neurological rejuvenation currently available, surpassing traditional longevity protocols.
More from All-In Podcast
View all
How We Grew Koch Industries to $150 Billion Without Going Public: Charles & Chase Koch
Charles and Chase Koch detail how Koch Industries grew from 300 employees to over 130,000 across 60 countries by becoming 'capability-bounded' rather than 'industry-bounded,' reinvesting 90% of profits, and applying principles of experimental discovery while learning from near-catastrophic failures.
Spencer Pratt on Fixing LA: Wildfires, Homelessness, Corruption & the Fight to Take It Back
Spencer Pratt recounts losing his Palisades home to wildfires caused by alleged government negligence, including an emptied reservoir and absent leadership, while detailing his subsequent lawsuit against the city and his fact-based campaign to unseat Mayor Bass.
Elon’s Anthropic Deal, The Next AI Monopoly?, “FDA for AI” Panic, Trading the AI Boom
Elon Musk's xAI has struck a landmark infrastructure deal leasing Colossus 1 data center capacity to Anthropic, instantly creating a hyperscaler revenue stream while solving Anthropic's critical compute constraints. The arrangement positions Anthropic to potentially reach $100 billion ARR this year and $1 trillion by 2027, creating what could become the most valuable monopoly in history if exponential growth persists.
OpenAI Misses Targets, Codex vs Claude, Elon vs Sam Trial, Big Hyperscaler Beats, Peptide Craze
OpenAI's missed user and revenue targets have sparked IPO concerns and internal leadership tension, but recent product improvements with ChatGPT 5.5 may give them an edge over Anthropic's struggling Opus 4.7 in the critical coding market. The entire sector faces severe power and compute constraints that favor hyperscalers while driving the need for algorithmic innovations like model pruning to meet exploding demand.